News
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.
Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday.
Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...
Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down Updated on: May 16, 2025 / 10:09 AM EDT / AP People using weight loss drugs like Ozempic and Wegovy drink less ...
A version of this article appears in print on May 17, 2025, Section B, Page 5 of the New York edition with the headline: Novo Nordisk, Its Stock Falling and Competition Rising, Will Replace Its C ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback